Key result
The I K,ACh blocker tertiapin-Q dose-dependently reduced AF incidence and episode duration, and prolonged atrial effective refractory period without affecting the QT interval in conscious dogs.
Why the study?
Does the I K,ACh blocker tertiapin-Q reduce atrial fibrillation incidence and duration in a canine model of chronic atrial fibrillation?
Does the I K,ACh blocker tertiapin-Q reduce atrial fibrillation incidence and duration in a canine model of chronic atrial fibrillation?
Tertiapin-Q, an I K,ACh blocker, demonstrates atrial-specific antiarrhythmic effects without ventricular proarrhythmic potential (QT prolongation) in a canine model of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Should not yet alter clinical AF management; extends preclinical evidence for atrial-selective I K,ACh inhibition.
Juhász et al. (2017) studied Atrial fibrillation. Tertiapin-Q (TQ) vs. Propafenone and dofetilide was evaluated on AF incidence, AF episode duration, atrial effective refractory period, AP duration, and QT interval. The I K,ACh blocker tertiapin-Q dose-dependently reduced AF incidence and episode duration, and prolonged atrial effective refractory period without affecting the QT interval in conscious dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: